Description:
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with
rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.
Title
- Brief Title: Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma
- Official Title: A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma
Clinical Trial IDs
- ORG STUDY ID:
2017002
- NCT ID:
NCT03372837
Conditions
- Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
Interventions
| Drug | Synonyms | Arms |
|---|
| Rituximab | | SyB L-0501 |
Purpose
The purpose of this study is to determine the efficacy of SyB L-0501 in combination with
rituximab in patients with recurrent/relapsed diffuse large B-cell lymphoma.
Detailed Description
Primary Objective is to determine the efficacy, as measured by overall response rate on the
basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m^2/day on
Day 2 and Day 3 in combination with rituximab at 375 mg/m^2 on Day 1 of each 21-day cycle in
patients with recurrent/relapsed diffuse large B-cell lymphoma.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| SyB L-0501 | Experimental | The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.
SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation. | |
Eligibility Criteria
Inclusion criteria Patients who satisfy all of the conditions listed below.
1. Patients with histopathologically confirmed diffuse large B-cell lymphoma (DLBCL)
except for transformed lymphoma on the basis of World Health Organization (WHO)
histological classification (4th ed., 2008).
2. Patients with documented Cluster of differentiation 20 (CD20)-positive for lymphoma
cells.
3. Patient with recurrent or relapsed DLBCL after R-CHOP-like theraphy as the firstline
therapy.
4. Patients with measurable lesions >1.5 cm in major axes.
5. Patients who are expected to survive for at least 3 months.
6. Patients aged 20 or above at the time informed consent is obtained.
7. Patient with Performance Status (P.S.) 0-1.
8. Patients with adequately maintained organ function.
Exclusion Criteria The study subject should be excluded if any one of the following
condition exists.
1. Patients who have been without treatment for less than 3 weeks after prior treatment.
2. Patients who can be candidates for autologous peripheral blood stem cell
transplantation at the discretion of the investigator.
3. Patients who received adequate prior treatments and did not respond to any of them.
4. Patient who received prior chemotherapy 3 regimens or more.
5. Patients with central nervous system (CNS) involvement or patients with clinical
symptoms suggestive of CNS involvement.
6. Patient with serious active infection.
7. Patient with serious complication.
8. Patient with complication or medical history of serious cardiac disease.
9. Patient with serious gastrointestinal symptoms.
10. Patient with malignant pleural effusion, pericardial effusion, or ascites retention.
11. Patients positive for hepatitis B surface (HBs) antigen, hepatitis C virus (HCV)
antibody, or HIV antibody.
12. Patient with serious bleeding tendency.
13. Patient with a fever of 38.0°C or higher.
14. Patients with, or confirmed in the past to have had, interstitial pneumonia, pulmonary
fibrosis, or pulmonary emphysema.
15. Patients with active multiple primary cancer or patients with a history of other
malignant cancer within the past 5 years, except for basal cell cancer of the skin,
squamous cell cancer, or cervical cancer in situ.
16. Patients with, or confirmed in the past to have had, autoimmune hemolytic anemia.
17. Patient who received bendamustin hydrochloride in the past.
18. Patients who received cytokine preparation such as erythropoietin or granulocyte
colony-stimulating factor (G-CSF) or blood transfusions within 2 weeks before the
examination at registration for this study.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 20 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Overall Response Rate |
| Time Frame: | up to 30 weeks |
| Safety Issue: | |
| Description: | Complete Response (CR) + Partial Response (PR) Determined on the Basis of Revised Response Criteria for Malignant Lymphoma (Revised RC 2007) |
Secondary Outcome Measures
| Measure: | Complete Response (CR) Rate |
| Time Frame: | up to 30 weeks |
| Safety Issue: | |
| Description: | Determined on the Basis of Revised Response Criteria for Malignant Lymphoma (Revised RC 2007) |
| Measure: | Progression Free Survival (PFS) |
| Time Frame: | up to 30 weeks |
| Safety Issue: | |
| Description: | PFS = day of the first PFS event - day of start of study treatment + 1 |
| Measure: | Duration of Response (DOR) |
| Time Frame: | up to 30 weeks |
| Safety Issue: | |
| Description: | DOR is the period from the date of achieving CR, or PR in the responders to the earliest onset date of any progression events calculated using the Kaplan-Meier estimator. The median and the 95% Confidence Interval (CI ) were calculated using Greenwood's formula. |
| Measure: | Overall Survival (OS) |
| Time Frame: | up to 30 weeks. |
| Safety Issue: | |
| Description: | Death due to any given cause was defined as an event. OS was calculated using the Kaplan-Meier estimator. The median and the 95% CI were calculated using Greenwood's formula. |
Details
| Phase: | Phase 3 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | SymBio Pharmaceuticals |
Trial Keywords
- Diffuse large B-cell lymphoma, rituximab, SyB L-0501, combination therapy
Last Updated
October 22, 2020
